ADARA announces expansion into the Nordics and plans for further European growth
6.11.2019 11:00:00 EET | Business Wire | Press release
ADARA, the leader in predictive traveller intelligence, today announces its expansion into the Nordic market for the first time, with the appointment of Jonas Jonsborg as Regional Manager, Nordics ADARA. In addition to the hire, ADARA also announces new recent data partnerships with Momondo, HotelsCombined and Cheapflights, which will further bolster its presence in Europe and support brands in the region.
Comprising over 850 million monthly unique traveller profiles across more than 200 leading travel brands, ADARA’s travel data co-op offers a holistic view of traveller behaviour and preferences along the entire customer journey. Since expanding into the region in 2013, ADARA has established a strong presence in Europe with the appointment of Curtis Nishijima as Managing Director, EMEA in 2018 and with key hires in the UK, Germany, France and Spain. ADARA has also seen an increase in its EMEA data profiles of 38% year on year, furthering bolstering their data presence in the region.
Building on the success in these markets, ADARA is now strengthening its presence in the Nordics, one of the fastest-growing travel markets in EMEA. Tourism in the Nordics has seen a significant rise in recent years; since 2014 the region had an annual growth of 6% - 8.5% in the number of hotel nights. The expansion seeks to enable travel brands and agencies to tap into the increased demand by tourists to and from the Nordic region by offering holistic data insights that can be used to create personalised marketing campaigns based on the complete view of the traveller.
The depth and applicability of ADARA’s data go beyond the travel and tourism industries. Other sectors in the Nordics such as luxury retail, financial services and automotive can also take advantage of ADARA’s understanding of traveller purchase behaviour and ADARA can provide these brands with solutions that improve marketing performance and help achieve deeper personalisation using actionable data.
In his new role, Jonas will spearhead ADARA’s expansion into the Nordic markets, drawing on his extensive understanding and experience in data and advertising technology. Jonas has previously held executive positions at Adform, Microsoft, Meetrics and Audience Project.
Jonas Jonsborg, Regional Manager at ADARA Nordics said: “The Nordic market is experiencing a huge gap, one that can only be filled by ADARA. The breadth and depth of the data is unparalleled, and will be invaluable to Nordic partners. I look forward to leveraging my experience in the Nordics and strong belief in ADARA’s value proposition to grow the business and establish new data partners in the region.”
Curtis Nishijima, Managing Director, EMEA said “Jonas has an exceptional range of skills that make him the perfect person to spearhead our Nordic expansion. He has a strong knowledge of the region and a deep understanding of our industry.
-ENDS-
About Momondo
Momondo is a travel fare aggregator and travel fare metasearch engine headquartered in Copenhagen. Momondo also operates a travel information blog, Inspiration. The website is part of the Kayak.com subsidiary of Booking Holdings.
About Hotelscombined
HotelsCombined, a unit of Booking Holdings, is a hotel metasearch engine founded in 2005. The site operates in over 42 languages, handles 130 different currencies and aggregates more than 2 million deals from hundreds of travel sites and hotel chains.
About Cheapflights
Cheapflights is a travel fare aggregator and travel fare metasearch engine headquartered in London, UK. The website is part of the Kayak.com subsidiary of Booking Holdings. Its websites publish flight prices, and compare prices from suppliers, including major airlines, through tiny travel agents.
About ADARA
ADARA. Know What Travellers Need Next.
ADARA empowers the world's leading travel brands to grow the industry together. Built on the world's richest travel data co-op, ADARA offers people-based insights for travel companies. Clients get a value-based understanding of their relationship with their customers, with travel patterns, trends and behavior from more than 850 million monthly unique traveler profiles across more than 200 of the world's top travel brands. ADARA delivers critical intelligence to activate personalisation and relevance throughout the customer journey for sustainable growth. Its offerings span the three core pillars – Learn, Act, Measure & Modify – to drive measurable outcomes at the customer level. https://www.adara.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191106005106/en/
Contact information
For more information please contact:
Ben Tozer / Louise Watson
adara@propellergroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom